' Introduction
Vogt-Koyanagi-Harada (VKH) disease, also known as uveomeningitic syndrome, is an idiopathic multisystem inflammatory disease with bilateral uveitis. Patients with bilateral anterior uveitis with vitiligo, poliosis, alopecia, and dysacousia were first described by Vogt in 1906 and then Koyanagi in 1929. 1,2 Harada described a case of posterior uveitis with exudative retinal detachment and pleocytosis of cerebrospinal fluid (CSF), in 1926. 3 Since these reports, it has become clear that these features are all contained within a single systemic inflammatory condition, which has become known as VKH disease. 4 ' Clinical Disease
As originally described, the Vogt-Koyanagi syndrome was characterized by bilateral anterior uveitis associated with alopecia, vitiligo, and dysacousia 1,2 and Harada disease by bilateral exudative uveitis mainly confined to the posterior segment with CSF pleocytosis. VKH is now considered a consolidated single entity of bilateral granulomatous panuveitis variably associated with vitiligo, alopecia, poliosis, auditory dysfunction, and central nervous system damage.
VKH evolves in phases, classified as prodromal, uveitic, convalescent, and chronic/recurrent. In the prodromal phase, patients develop nonspecific systemic symptoms such as fever, headache, nausea, meningismus, vertigo, and dysacusis. Rarely, focal neurologic signs such as cranial nerve palsies and optic neuritis can occur. Spinal tapping, for collection of CSF, typically reveals an increase in inflammatory cells (pleocytosis) with a predominance of lymphocytes.
Three to 5 days after the prodromal phase, the acute ocular, or uveitic, phase begins. Ocular symptoms include blurred vision, photophobia, and ocular pain. Bilateral, granulomatous uveitis, and particularly choroiditis, is common. Characteristic exudative retinal detachments are seen as multiple, discrete, shallow elevations of the neural retina with small folds. These can become bullous in advanced cases. The optic nerve may be swollen and hyperemic in up to 87% of patients. 5 There is a marked inflammatory reaction to the choroid, with relative sparing of the choriocapillaris and overlying retina. 6 But, inflammation in the vitreous, with spillover into the anterior chamber, is common. Mutton fat keratic precipitates and nodules on the iris surface and papillary margins can develop. Swelling of the ciliary body may displace the lens-iris diaphragm forward and shallow in the anterior chamber. This can result in elevated intraocular pressure and episodes of angle closure. The ocular manifestations are clinically, histologically, and angiographically similar to those of sympathetic ophthalmia. 6 In the convalescent stage of the disease, after appropriate treatment, the exudative detachments gradually subside and the uveitis abates. As the uveal swelling subsides, depigmentation of the choroid due to loss of melanocytes produces the typical orange-red ''sunset glow'' appearance of the fundus. Multiple scattered, discrete, depigmented retinal pigment epithelial lesions are seen. These were originally described by Harada 3 to represent Dalen-Fuchs nodules clinically, but Inomata and Rao 7 showed that they represent localized areas of disappearance of the retinal pigment epithelial cells. The limbus can also become depigmented (Suguira sign). 8 The convalescent stage can persist for months.
VKH uveitis can be prolonged or can recur. Most vision-threatening complications occur in the chronic recurrent phase. Recurrent anterior uveitis in the absence of posterior inflammation is typical. 9 Retinal vasculitis or arterio-venous anastomoses can develop in response to prolonged inflammation. Choroidal neovascular membranes (CNVM) and hemorrhage can occur; this is a major permanent vision-limiting complication of the disease. 10 Posterior synechiae and iris atrophy can also develop in response to prolonged inflammation. The ciliary body band loses pigmentation, as seen on gonioscopy. Long-term ocular complications of the disease and treatment also include cataracts, typically posterior subcapsular, and secondary angle closure. 10 Subretinal fibrosis, unrelated to CNVM, has also been described. 10, 11 A review of complications in 101 patients at the Doheny Eye Institute showed the rate of cataract formation at 44%, glaucoma at 29%, CNVM at 15%, and subretinal fibrosis at 8% of patients. 10 Those patients with at least 1 complication had a longer duration of disease. This same study found that visual acuity on presentation was a significant predictor of final visual outcome. Eyes with an increasing number of ocular complications were more likely to have worse final visual acuity. At final follow-up, 50% of eyes were found to have vision of 20/40 or better and 70% had better than 20/200 vision. 10 Rubsamen and Gass 12 found increasing age, chronic inflammation necessitating prolonged treatment, and CNVM to be predictors of poor outcome.
Systemic disease is a prominent feature of VKH. The most commonly involved sites are the meninges, skin, and inner ears. Neurologic symptoms can occur during the prodromal state. Meningeal involvement typically presents with headache and stiff neck. Spinal tapping reveals pleocytosis 1 to 2 weeks before ocular findings. Encephalitis may occur with cranial nerve palsies, aphasia, personality changes, loss of consciousness, and seizures. Auditory symptoms are common and include tinnitus, high-frequency hearing loss, and vertigo. The convalescent stage can result in skin involvement. Vitiligo of the face, hands, shoulder, breast, and back are common. Alopecia and poliosis can also occur.
Other conditions have been associated with VKH. There is an increased prevalence of keratoconjunctivitis sicca in patients with VKH as compared with controls, with a few of these patients satisfying the criteria for Sjogren syndrome. 13 A series of 3 patients with onset of VKH and Guillain-Barre syndrome within weeks has been described.
14 A high incidence of glucose intolerance has been described in the acute phase of the disease before the onset of corticosteroid therapy. 15 This was shown to improve with steroid treatment. 15 ' Pathogenesis VKH occurs most commonly in pigmented individuals such as Asians, Hispanics, Native Americans, Asian Indians, and Middle Easterners. It is rare in whites, but, interestingly, also rare in Africans. It seems to be the genetic predisposition in these individuals, rather than the amount of pigment, which is the predisposing factor. Women are affected slightly more often than men. The disease is most common in the third to fifth decades of life, but can affect individuals in all age groups, including the pediatric population.
There is a genetic link to HLA-DR4 and HLA-Dw53 with the most significant risk allele being HLA-DRB1*0405. 16, 17 This association has been found in multiple races including Japanese, 18 Hispanic, 19 Korean, 20 Italian, 21 Mexican, 22 and Chinese. 23 Further evidence of a genetic link includes a pair of monozygotic twins with the syndrome. 24 It has been hypothesized that VKH represents a T-cell-mediated autoimmune disorder against melanocytes of all organ systems. 6, 25, 26 Tyrosinase or tyrosinase-related proteins have been implicated as target antigens on the melanocyte. 27 Studies have shown that tyrosinase family protein in a rat model can induce an autoimmune disease strongly resembling human VKH and that lymphocytes of VKH patients are reactive to tyrosinase family proteins.
Pathologic analysis demonstrates a diffuse non-necrotizing granulomatous infiltration of the uvea that spares the choriocapillaris. Lymphocytes predominate, but epithelioid cells, plasma cells, and multinucleated cells are also present. 29 The epithelioid and giant cells contain melanin. Dalen-Fuchs nodules consisting of macrophages, epithelioid cells, and lymphocytes with an alteration in the RPE can be seen in the chronic phase. 30 It is unclear what triggers the immune system of a patient with the genetic predisposition to mount an autoimmune response against the target cells and antigens. Some have hypothesized a viral trigger, such as the Epstein-Barr virus. The meningismus and tinnitus that present before the onset of uveitis is consistent with this notion, and Epstein-Barr virus DNA has been isolated from the vitreous of patients with VKH. 31 VKH has been reported after cutaneous injury, supporting a theory that it may result from systemic sensitization to shared melanocytic antigens. 32 
' Diagnosis
A differential diagnosis of the ocular manifestations which can be seen in VKH should include sympathetic ophthalmia, idiopathic central serous chorioretinopathy, acute leukemia, primary intraocular B-cell lymphoma, metastatic carcinoma, uveal melanocytic proliferation associated with systemic carcinoma, idiopathic uveal effusion syndrome, posterior scleritis, acute posterior multifocal placoid pigment epitheliopathy, multiple evanescent white dot syndrome, Behcet disease, Lyme disease, sarcoidosis, and benign reactive lymphoid hyperplasia of the uveal tract. Systemic blood work and physical exam to rule out systemic disease and malignancy should be performed.
Fluorescein angiography (FA) typically shows patchy areas of delayed choroidal perfusion. This is followed by the highly characteristic appearance of numerous pinpoint spots of staining at the level of the RPE, which coalesce into larger placoid areas of hyperfluorescence. With treatment, this pattern resolves. Later in the disease, window defects in the RPE are seen on FA. The optic nerve head can show leakage in the acute phase of the disease. Indocyanine green angiography can better demonstrate a decrease in the choroidal circulation and choroidal neovascularization. 33, 34 These findings, however, are not specific for VKH.
Spinal tapping reveals pleocytosis of the CSF with elevation of protein levels in up to 80% of patients within a week and 97% of patients within 3 weeks of inflammation. The pleocytosis is mainly lymphocytic. 35 Ultrasonography of the eyes reveals low to medium reflective thickening of the choroid posteriorly 36 differentiating VKH from idiopathic uveal effusion and metastatic carcinoma, which tend to have higher reflectivity. Ultrasound can also show serous retinal detachments, vitreous opacities, and thickening of the sclera or episclera. 36 These findings typically resolve with therapy. 36 Ultrasound biomicroscopy has been used to study the ciliary body during the varying phases of VKH. In the active phase of the disease, a shallow anterior chamber with thickened ciliary body is seen. Internal reflectivity of the ciliary stroma is low. Some patients show ciliochoroidal detachment. As patients recover, the pars plana remains thickened. In the remission phase, the ciliary body returns to normal thickness, with homogeneous internal reflectivity and normal delineation of the ciliary processes. 37 MRI has not proved useful in the diagnosis. Diagnostic criteria were initially proposed 38 and have been subsequently revised. 39 The revised criteria subdivide definite VKH into complete and incomplete categories based on the manifestations seen ( Table 1 ). The initial criterion for diagnosis is lack of penetrating trauma (to distinguish this entity from sympathetic ophthalmia). The second, seemingly obvious criterion, is the exclusion of systemic disease such as sarcoidosis, Lyme, tuberculosis, and lymphoma, which could mimic VKH. The third criterion requires bilateral ocular disease (even if subtle). This criterion can be satisfied by early manifestations of the disease such as choroiditis manifesting as subretinal fluid or serous detachments, choroidal thickening on ultrasound, or typical FA findings. Patients presenting late can meet this criterion with a history of prior early signs and characteristic features such as sunset glow fundus, Sugiura sign, nummular chorioretinal depigmented scars, RPE clumping, or recurrent or chronic anterior uveitis. The final 2 criteria include neurologic/auditory findings such as meningismus, tinnitus, or CSF pleocytosis, and integumentary findings including alopecia, poliosis, or vitiligo. Incomplete VKH was defined as the first 3 criteria and either neurologic or integumentary findings. Probable VKH was defined as the first 3 criteria without either neurologic or integumentary findings. The use of the terms ''typical'' and ''atypical'' VKH and also of the term ''Harada disease'' when describing cases of isolated posterior pole findings has been discouraged. 39 
' Treatment
The standard initial therapy for VKH is with prompt, aggressive corticosteroids. Typical dosing regimens range from 1 to 2 mg/kg/d of prednisone orally. 40 Early therapy with a slow taper, averaging q6 months, has been shown to improve the prognosis by reducing the length of disease, the incidence of a convalescent phase, and decreasing extraocular manifestations of VKH. 12, 41, 42 Anterior segment inflammation is treated with topical steroid drops. If the retinal detachments do not respond to oral corticosteroid therapy, intravenous methylprenisolone therapy may be appropriate.
Some investigators argue for initial therapy with pulse highdose intravenous corticosteroids in all patients. 43, 44 A study using OCT to follow the progress of serous detachment after treatment with 3 days of pulse intravenous therapy followed by oral prednisone showed a decrease in serous detachment as early as 3 hours after intravenous infusion. 44 The study showed almost complete resolution of serous detachment in 18 of 18 eyes by day 7 of this regimen. 44 Despite appropriate treatment with steroid therapy, many patients suffer recurrences and associated complications. Long-term treatment with corticosteroids with slow tapers will inevitably result in some of the numerous possible inherent complications associated with steroid therapy. Therefore, nonsteroidal immunomodulatory therapy (IMT) has become essential in the treatment of VKH. The American Uveitis Society, after an evidence-based exercise reviewing literature, concluded that VKH requires IMT to control the inflammation. [45] [46] [47] Likewise, the International Uveitis Study Group consensus panel placed VKH on a list of diseases for which immunosuppressive chemotherapy was considered ''mandatory.'' [48] [49] [50] Foster and Vitale 50 reiterated this conclusion by including VKH in a list of ''absolute'' indications for immunosuppressive chemotherapy.
Cytostatic agents, such as cyclosporine, are a logical treatment to suppress T-cell-mediated immunity. As such, cyclosporine has been used most extensively and successfully to treat VKH. It has proven effective in many cases of steroid-resistant inflammation in VKH. 12, 40, [51] [52] [53] [54] Cyclosporine dosing should be limited to 5 mg/kg/d to minimize the potential for renal and hepatic toxicity. Tacrolimus is another potential cytostatic agent treatment option. Cytotoxic agents such as cyclophosphamide, chlorambucil, and azathioprine have also been used successfully. 40, [55] [56] [57] In a review of 13 patients treated at the Massachusetts Eye and Ear Infirmary, Paredes and Foster 47 compared patients who had undergone prolonged steroid therapy with or without the delayed addition of IMT versus those who received prompt IMT (within 6 mo of diagnosis). They found that 7 of 8 patients in the prompt IMT group improved visual acuity from presentation whereas 3 of 5 with prolonged steroid therapy without prompt IMT suffered deterioration in final visual acuity. After a review of their data and the literature, the authors recommended that IMT should be considered as a first-line therapy for VKH.
A pilot study showed daclizumab (an anti-interleukin-2 receptor antibody) to be safe and effective at controlling inflammation in a group of 10 uveitis patients that included 2 patients with VKH. 58 A study using mycophenolate mofetil (Cellcept), an immunosuppressive agent that prevents the replication of T and B lymphocytes, was performed by Foster's group, with the conclusion that it was safe and effective at controlling chronic ocular inflammatory disorders, and in particular, 2 of 3 patients with VKH demonstrated control of inflammation for over 6 months. 59 One report describes a case that was resistant to, and intolerant of, long-term steroid therapy. The patient could not tolerate cyclophosphamide due to the development of hemorrhagic cystitis. The addition of azathioprine to steroids did not resolve the inflammation. In this patient, intravenous immunoglobulin was used successfully and resulted in a rapid improvement in neurologic findings. The patient did experience recurrences requiring retreatment. 60 In light of the available literature and recommendations of the expert panels, it is advisable to include IMT in the treatment regimen of VKH. See Table 2 for a list of mechanisms, dose ranges, potential side effects, and necessary monitoring for these immunomodulatory therapies. 45 Ophthalmic complications may require treatment beyond systemic therapy. CNVM may require photocoagulation therapy; however, success is often limited for this problem. Acute angle closure due to uveal swelling typically resolves with appropriate systemic steroid therapy, but laser and/or surgical iridectomy is sometimes required. Steroid-related glaucoma and chronic angle closure resulting from posterior synechiae due to chronic inflammation may require topical therapy or surgical management such as trabeculectomy or drainage implants.
Cataract extraction in patients with uveitis can be challenging. Posterior synechiae and shallow anterior chambers make the surgical procedure difficult. Synechiolysis, pupil stretching, and iris hooks may be necessary. Peripheral iridectomy should be considered in patients at risk for angle closure. The safety of intraocular lens use is not completely known. A large retrospective study reported success using phacoemulsification followed by heparin-surface modified and acrylic foldable intraocular lenses 61 in patients with VKH. The authors stressed the importance of preoperative and postoperative control of inflammation. Moorthy et al 40 recommend a period of at least 2 to 3 months of no acute ocular inflammation followed by 1 week of preoperative high-dose corticosteroids, with a postoperative taper. ' 
Summary
VKH is a multisystem inflammatory disorder which attacks ocular, auditory, nervous, and integumentary systems. The pathogenesis seems to be related to autoimmunity against melanocyte antigen in genetically predisposed individuals. The diagnosis is made on clinical grounds, with various adjunctive ocular and systemic tests supporting the diagnosis. Treatment begins with aggressive corticosteroids but may ultimately require IMT. Prognosis is guarded with multiple ocular complications potentially limiting vision. 
